With only $41 million in cash, Tvardi Therapeutics may need to raise additional funds within a one-year period. Click here to ...

In the wake of the Tories’ latest disaster, Kevin Crane analyses the historically adaptive nature of the party, and why now ...

Ardelyx (ARDX) is trading in the pharmaceutical sector, and its recent stock performance has caught the eye of many investors. Shares have seen movement in the past month, prompting a closer look at ...